What Thirty Years Of EBVST Teaches Us About Off-The-Shelf Cell Therapy

By Ivan Horak, M.D.

Autologous CAR-T therapy has transformed cancer treatment, validating the idea that engineered immune cells can produce durable therapeutic responses in patients with otherwise limited options. Yet as the field matures, its success has brought a new challenge into focus: how to make cell therapy broadly accessible.

That success has been most visible in hematologic malignancies, where targets are often more accessible and clinical responses have been most compelling. The question facing the industry today is no longer whether cellular therapies can work, but whether they can be manufactured, delivered, and scaled in ways that allow larger patient populations, including patients with solid tumors, to benefit.

As developers pursue answers, much of the discussion has centered on gene editing, synthetic biology, and increasingly sophisticated cellular engineering. Those technologies are advancing rapidly and will undoubtedly play an important role in the next generation of therapies. At the same time, there may be value in revisiting a body of clinical experience that predates many of today's allogeneic cell therapy programs.

For more than three decades in oncology drug development, I have learned that some advances emerge from entirely new technologies, while others come from reexamining observations that have been hiding in plain sight. The clinical experience with Epstein-Barr virus-specific T cells (EBVSTs) may represent the latter.

EBVSTs are immune T cells selected and expanded to recognize Epstein-Barr virus antigens. Used as adoptive cell therapy, they are designed to restore targeted immune surveillance by eliminating EBV-infected or EBV-associated malignant cells. They have been studied most extensively in transplant recipients with EBV-driven post-transplant lymphoproliferative disorder (PTLD), a potentially life-threatening consequence of severe immunosuppression.

For more than 30 years, transplant physicians have used EBVSTs to manage complications associated with profound immunosuppression. While originally developed for a different clinical purpose, these therapies have generated one of the longest-running bodies of evidence involving donor-derived, antigen-specific T cells in human patients.

That history is increasingly relevant as the cell therapy field confronts the limits of today’s dominant model. Autologous CAR-T has shown what engineered immune cells can achieve, but its individualized manufacturing process also highlights why scalable, off-the-shelf approaches have become so important.

The Challenge Behind Autologous Success

The scientific achievement represented by autologous CAR-T therapy is undeniable. However, the model incorporates several structural limitations that become increasingly important as the field seeks broader adoption.

Manufacturing begins with collection of a patient's own T cells. Those cells must then be transported, genetically modified, expanded, tested, released, and ultimately returned to the treatment center. Depending on the product and clinical circumstances, this process can take weeks.

For patients with rapidly progressing disease, time is not a trivial variable. Some require bridging therapies while awaiting manufacturing completion, while others may experience disease progression during the waiting period.

The quality of the starting material also varies considerably. Many patients eligible for CAR-T therapy have received multiple prior treatments and may have compromised immune systems. As a result, the cellular material entering manufacturing can differ significantly from patient to patient, creating challenges for consistency and scalability.

These realities do not diminish the importance of autologous therapy. Rather, they underscore the need to explore manufacturing models capable of supporting larger patient populations and broader clinical applications.

Solid tumors represent perhaps the greatest test of that ambition. If cellular therapies are to become a widely accessible modality across oncology, off-the-shelf approaches will likely play an increasingly important role.

The Rise Of Allogeneic Cell Therapy

The appeal of allogeneic therapy is straightforward. Instead of creating a custom product for each patient, manufacturers could use healthy donor cells to generate large numbers of doses in advance, making therapy available when needed rather than after a manufacturing cycle.

Such a model offers potential advantages in scalability, consistency, logistics, and access.

Yet allogeneic approaches face a fundamental biological challenge. Donor-derived T cells possess receptors capable of recognizing differences between donor and recipient tissues. This creates the risk of graft-versus-host disease (GvHD), one of the principal concerns in any allogeneic cellular strategy.

At the same time, donor cells must contend with the recipient’s immune system, which can identify and eliminate foreign cells before they achieve sustained therapeutic activity.

To address these challenges, many developers have embraced extensive genetic engineering. Technologies such as CRISPR and TALEN are commonly used to disrupt endogenous T-cell receptors, reducing the likelihood of alloreactivity. Additional modifications are often incorporated to improve persistence and limit immune rejection.

These approaches represent remarkable scientific progress. However, they also reflect an underlying assumption: that allogeneic cell therapy requires substantial cellular redesign to be safe and effective.

The history of EBV-specific T cells suggests there may be another perspective worth considering.

A Clinical Experiment Hidden In Plain Sight

The origins of EBVST therapy lie in transplant medicine.

Patients undergoing hematopoietic stem cell transplantation or receiving solid organ transplants often require profound immunosuppression. While necessary to prevent rejection, immunosuppression can permit reactivation of latent viral infections, including Epstein-Barr virus.

EBV reactivation is a major contributor to PTLD and Epstein-Barr virus is present in most PTLD cases, and both EBV serologic status and the depth of T-cell immunosuppression are recognized risk factors for disease development.

As clinicians searched for targeted ways to restore immunity, they developed methods for generating T cells directed specifically against EBV antigens. These virus-specific cells were infused into immunocompromised patients to control viral replication and treat PTLD.

Over time, donor-derived and third-party EBV-specific T cells were evaluated across numerous clinical studies and treatment programs, generating one of the largest bodies of experience for any virus-specific cellular therapy.

The accumulated evidence revealed an important observation: partially HLA-matched EBV-specific T cells could produce therapeutic responses while maintaining a generally favorable safety profile. Studies evaluating donor-derived and third-party products have consistently reported low rates of clinically significant GvHD and other severe toxicities.

A study published in the January 2020 issue of The Journal of Clinical Investigation evaluated third-party, banked, partially HLA-matched EBV-specific cytotoxic T cells in 46 patients with rituximab-refractory EBV-associated post-transplant lymphoproliferative disease following hematopoietic-cell or solid-organ transplantation. Investigators reported no significant treatment-related toxicities, with only one patient developing grade 1 skin graft-versus-host disease; the study also reported complete or sustained partial remissions in 68% of hematopoietic-cell transplant recipients and 54% of solid-organ transplant recipients.

For developers focused on allogeneic platforms, these observations raise an obvious question: how much of this favorable safety profile derives from the biology of the cells themselves?

Understanding The Biology

The biological characteristics of EBVSTs help explain why they continue to attract scientific interest.

Unlike naïve T cells, which possess a broad and diverse receptor repertoire, EBVSTs are largely derived from antigen-experienced memory T-cell populations. Through prior exposure to Epstein-Barr virus, these cells develop receptor repertoires focused on viral targets.

One proposed explanation for their favorable safety profile is that these memory T cells are already trained to recognize viral targets. That specialization may reduce the likelihood that they will react broadly against patient tissues compared with less specialized donor T-cell populations.

This hypothesis is consistent with decades of clinical observation, although the precise mechanisms underlying the behavior, persistence, and safety of EBV-specific T cells remain an active area of investigation.

For the broader cell therapy field, this highlights an important strategic consideration. Safety may depend not only on what is engineered into a cell, but also on the biological characteristics of the starting cell population.

What Makes The EBVST Experience Worth Revisiting?

The significance of EBVSTs is not that they provide a ready-made solution to every challenge facing allogeneic cell therapy. Rather, they offer a rare opportunity to examine how a specialized population of donor-derived T cells has behaved across decades of clinical use.

In biotechnology, longitudinal human experience of this kind is uncommon.

The history of EBVSTs suggests that cellular identity may deserve as much attention as cellular engineering. Over the past several years, much of the industry's effort has focused on modifying cells to overcome biological limitations. The EBVST experience raises a complementary question: are there naturally occurring cell populations that already possess characteristics favorable for allogeneic use?

The answer remains uncertain. However, the clinical record suggests the question is worth asking.

The Solid Tumor Test

Perhaps the most important question facing any next-generation cellular platform is whether it can succeed where previous approaches have struggled: solid tumors.

The obstacles are well known. Solid tumors employ multiple mechanisms to suppress immune responses, including inhibitory signaling pathways, dense stromal barriers, metabolic constraints, immune-evasion mechanisms, tumor heterogeneity, and antigen escape. Even when engineered cells reach a tumor, maintaining meaningful activity within that environment remains difficult.

For this reason, caution is warranted when extrapolating from experience in viral disease or transplant-associated malignancies.

Success against PTLD does not automatically predict success against breast cancer, lung cancer, colorectal cancer, or other solid tumors. Significant scientific and clinical questions remain unresolved. These include persistence, trafficking into tumor tissue, resistance to host rejection, and the ability to maintain activity within a suppressive tumor microenvironment.

For allogeneic approaches, these questions are especially important because therapeutic activity depends not only on initial potency but also on whether transferred cells can expand sufficiently, persist long enough, and remain functional in a hostile tumor microenvironment.

Whether virus-specific memory T cells can help overcome those barriers remains a question for clinical investigation rather than assumption.

Engineering With Biology Rather Than Against It

The development of cell therapy has often followed a pattern of increasing engineering complexity. As new challenges emerge, additional modifications are introduced to address them.

That trend has produced remarkable innovation. It has also prompted a broader conversation about the balance between engineering and biology.

One perspective emphasizes redesigning cellular systems to overcome natural limitations. Another focuses on identifying naturally specialized cellular populations and preserving qualities that evolution has already optimized.

The history of EBV-specific T cells aligns with the latter view.

Their clinical experience suggests that carefully selected biological platforms may possess advantages that cannot be fully replicated through engineering alone. Rather than serving as a replacement for innovation, such platforms may provide a foundation upon which future innovations can be built.

The most effective next-generation therapies may ultimately combine both approaches, pairing sophisticated engineering with cellular populations that already exhibit favorable biological characteristics.

A Broader Lesson For Cell Therapy Leaders

One of the recurring themes in biotechnology is the tendency to view innovation primarily through the lens of new technologies. New tools matter, but so does the ability to recognize when existing clinical experience contains lessons that remain underappreciated.

The history of EBV-specific T cells offers such a lesson.

Long before allogeneic CAR-T programs became a major focus of investment, transplant physicians were administering partially matched donor-derived T cells and documenting both their benefits and limitations. Those efforts generated a substantial body of evidence regarding the behavior of specialized allogeneic T-cell populations in humans.

For today's cell therapy leaders, this experience may be valuable not because it provides definitive answers, but because it broadens the conversation.

As developers evaluate next-generation allogeneic platforms, important questions extend beyond which genetic modifications can be introduced into a cell. Equally important are questions about which cell populations are selected, how their underlying biology influences clinical behavior, and whether natural immune specialization can be leveraged rather than replaced.

In that sense, the story of EBVSTs is larger than transplant medicine. It illustrates how progress can emerge from connecting historical clinical observations with modern technological capabilities.

What Cell Therapy Leaders Should Watch Next

Recent safety-related pauses in CAR-T development programs serve as a reminder that the future of cell therapy will be shaped not only by efficacy, but also by how effectively developers manage immune-mediated risk. Reports of clinical holds following severe immune reactions underscore the reality that cellular therapies remain biologically complex interventions, even as manufacturing and engineering capabilities continue to advance. As the field expands into earlier lines of treatment and broader patient populations, the tolerance for severe toxicity may become increasingly limited. Safety, predictability, and long-term clinical experience will likely become increasingly important considerations in platform development.

Another encouraging area is in vivo CAR-T, which aims to generate CAR-T cells directly inside the patient rather than through ex vivo manufacturing. While still an emerging platform, it may become especially relevant in autoimmune disease and, over time, could also inform new approaches in malignancies.

The future of cell therapy will undoubtedly be shaped by advances in gene editing, synthetic biology, manufacturing science, and immunology. Yet progress may also depend on recognizing lessons that have already emerged from clinical practice.

The experience with EBV-specific T cells represents one of the most extensive real-world evaluations of allogeneic T-cell therapy in medicine. Long before today's enthusiasm for off-the-shelf products, transplant physicians were administering partially matched donor-derived T cells and documenting their behavior in patients.

That experience does not eliminate the challenges facing allogeneic therapy, nor does it guarantee success in solid tumors. Questions surrounding persistence, immune rejection, trafficking, and efficacy remain active areas of investigation.

What it does provide is a valuable clinical precedent.

As developers search for scalable cellular therapies capable of reaching larger patient populations, the field may benefit from looking not only at what can be engineered into a cell, but also at what decades of human clinical experience have already revealed. The lessons of transplant medicine may prove increasingly relevant in the years ahead.

About the Author:

Ivan Horak, MD, is a physician-scientist and biotechnology executive with more than three decades of experience in oncology drug development, translational medicine, and immunotherapy. He is founder and CEO of Tikva Allocell, a Singapore-based cell therapy company focused on advancing allogeneic, off-the-shelf cellular therapies. Dr. Horak has held senior leadership positions across biotechnology and pharmaceutical organizations, focusing on advancing innovative cancer therapies from scientific discovery through clinical development.